We are live on
!
Find out more
OCA
Octagon Capital Advisors Portfolio holdings
AUM
$904M
1-Year Est. Return
737.04%
This Fund
S&P 500
This Quarter
Est. Return
+20.93%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$483M
AUM Growth
+$217M
(+82%)
Cap. Flow
+$193M
Cap. Flow
% of AUM
40.03%
Top 10 Holdings %
Top 10 Hldgs %
66.04%
Holding
36
New
8
Increased
7
Reduced
–
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$36.5M |
| 2 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$27.3M |
| 3 |
BridgeBio Pharma
BBIO
|
+$21.8M |
| 4 |
Vera Therapeutics
VERA
|
+$17.6M |
| 5 |
Zai Lab
ZLAB
|
+$17.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$7.69M |
| 2 |
Foghorn Therapeutics
FHTX
|
+$911K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.38% |
| 2 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
| $79.4M | 16.44% |
1,256,265
+707,891
| +129% | +$36.5M |
|
|
NBP
2
NovaBridge Biosciences American Depositary Shares
NBP
$205M
| $79.2M | 16.4% |
943,156
+413,106
| +78% | +$27.3M |
|
3
Curis
CRIS
$9.53M
| $28.9M | 5.99% |
8,957
+3,636
| +68% | +$16.4M |
|
|
4
BridgeBio Pharma
BBIO
$16.5B
| $23.2M | 4.81% |
+380,928
| New | +$21.8M |
|
5
Arcus Biosciences
RCUS
$3.57B
| $20.9M | 4.32% |
760,164
+360,164
| +90% | +$10.3M |
|
6
4D Molecular Therapeutics
FDMT
$526M
| $20M | 4.15% |
831,267
+452,979
| +120% | +$13.9M |
|
|
7
Zai Lab
ZLAB
$2.17B
| $19.4M | 4.01% |
+109,335
| New | +$17.6M |
|
8
Celldex Therapeutics
CLDX
$2.77B
| $18.8M | 3.89% |
561,398
| – | – |
|
|
9
Vera Therapeutics
VERA
$2.54B
| $15M | 3.11% |
+1,132,671
| New | +$17.6M |
|
|
XLRN
10
DELISTED
Acceleron Pharma
XLRN
| $14.1M | 2.92% |
112,363
| – | – |
|
11
Arvinas
ARVN
$518M
| $13.7M | 2.85% |
178,500
| – | – |
|
12
Dyne Therapeutics
DYN
$4.04B
| $12.3M | 2.54% |
583,649
| – | – |
|
13
Century Therapeutics
IPSC
$381M
| $11.8M | 2.45% |
+403,523
| New | +$10.2M |
|
14
Gossamer Bio
GOSS
$66.5M
| $11.5M | 2.38% |
1,413,138
| – | – |
|
|
RNAM
15
DELISTED
Avidity Biosciences
RNAM
| $11M | 2.29% |
446,641
| – | – |
|
16
Stoke Therapeutics
STOK
$1.82B
| $9.99M | 2.07% |
+296,822
| New | +$10.5M |
|
|
AMAM
17
DELISTED
Ambrx Biopharma Inc
AMAM
| $8.82M | 1.83% |
+450,000
| New | +$7.67M |
|
18
PMV Pharmaceuticals
PMVP
$66.1M
| $8.54M | 1.77% |
250,000
| – | – |
|
|
CNTB
19
Connect Biopharma Holdings
CNTB
$135M
| $7.29M | 1.51% |
373,492
| – | – |
|
20
Taysha Gene Therapies
TSHA
$1.59B
| $6.79M | 1.41% |
320,440
| – | – |
|
21
Cardiff Oncology
CRDF
$64.3M
| $6.54M | 1.35% |
982,753
+332,753
| +51% | +$2.82M |
|
|
IMA
22
ImageneBio Inc
IMA
$63.1M
| $5.62M | 1.16% |
33,333
| – | – |
|
23
Monte Rosa Therapeutics
GLUE
$1.92B
| $5.4M | 1.12% |
+238,045
| New | +$4.85M |
|
24
Design Therapeutics
DSGN
$736M
| $4.97M | 1.03% |
250,000
| – | – |
|
|
RXDX
25
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $4.91M | 1.02% |
200,000
| – | – |
|
Similar funds
AIC
AOWM
SWM
EI
PIP
PSCM
EWM
PC
Octagon Capital Advisors's Q2 2021 Portfolio in Review
As of Q2 2021, Octagon Capital Advisors held 36 positions worth $483M, up 82% from $265M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Octagon Capital Advisors deployed $193M of net new capital in Q2 2021, opening 8 new positions and adding to 7 existing holdings. Its largest new stake was BridgeBio Pharma: 380,928 shares worth $23.2M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Financials.
On the sell side, the most notable exit was ChemoCentryx, Inc., an estimated $7.69M sold.
- Octagon Capital Advisors's largest Q2 2021 buy was BridgeBio Pharma: 380,928 shares worth $23.2M.
- Octagon Capital Advisors added most to Apellis Pharmaceuticals in Q2 2021, an estimated $36.5M increase.
- Octagon Capital Advisors fully exited ChemoCentryx, Inc. in Q2 2021, selling an estimated $7.69M.
- Octagon Capital Advisors's ten largest holdings make up 66% of its $483M portfolio in Q2 2021.
- Octagon Capital Advisors opened 8 new positions and closed 2 in Q2 2021.
- Octagon Capital Advisors's portfolio value rose 82% quarter-over-quarter to $483M.
Based on Octagon Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.